Bavarian Nordic A/S - ADR does not currently pay a dividend. The outlook for the Pharmaceuticals sub-industry is positive as the world returns to normalcy and demand for electives ... to arise getting ...
Going forward, we will focus on key business areas that implement a simplified organization to improve our cost structure and ...
Going forward, we will focus on key business areas that implement a simplified organization to improve our cost structure and enable key actions, including meeting the opioid crisis demand and ...
R&D expense of $15 million, reflecting the impact of the Travel Health divestiture to Bavarian Nordic as well as the ... as we expect continued strong demand for NARCAN in the US public interest ...
R&D expense of $15 million, reflecting the impact of the Travel Health divestiture to Bavarian Nordic, as well as the ... as we expect continued strong demand for NARCAN in the US public interest ...
Going forward, we will focus on key business areas that implement a simplified organization to improve our cost structure and enable key actions, including meeting the opioid crisis demand and ...
Going forward, we will focus on key business areas that implement a simplified organization to improve our cost structure and enable key actions, including meeting the opioid crisis demand and ...
Two European partners will soon be vying for dominance in a new battleground: vaccines to protect travelers against a painful ...
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN® smallpox vaccine to the strategic ...
The global vaccines market is poised for unprecedented growth, with a projected Compound Annual Growth Rate (CAGR) of 6.6%, catapulting it to an impressive USD 80.8 billion by 2033. This surge marks a ...